FourKites Releases New Capabilities for Global Air Freight Visibility
Leading supply chain visibility company FourKites has introduced several powerful new capabilities to enhance air freight visibility around the globe. These new features, including industry-leading dashboards and unique views into carrier events, split shipments and booking details, complement FourKites’ existing end-to-end international visibility solutions to help shippers proactively build routes based on in-transit inputs, all in a single user interface.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230508005742/en/
FourKites Releases New Capabilities for Global Air Freight Visibility (Photo: Business Wire)
Heavyweight air is commonly used by shippers and freight forwarders to transport high-value goods, as well as to expedite shipments when delays occur. Now, FourKites’ unmatched data intelligence and enhanced air solutions help shippers optimise their supply chain faster and with greater accuracy than ever before — all seamlessly on the FourKites platform via end-to-end multimodal visibility.
New notable air visibility features provide the following benefits:
- Carrier Events View allows shippers to compare data from carrier websites against FourKites’ milestones, events and highly accurate Dynamic ETAs® for Air that leverage machine learning and AI algorithms. This allows supply chain partners to increase workforce efficiencies and maximise collaboration based on high-quality, end-to-end visibility data.
- Easy Load Creation enables shippers to generate air shipments with limited information, thereby accelerating their time to value with visibility.
- New Dashboards — including a Transit Time Dashboard, On-time Performance Dashboard, Milestone Dashboard, Customer Health Dashboard and Lane Dashboard — allow for more strategic decision-making through insights on carrier and lane performance, tracking health and more.
- Split Shipments let customers track shipments that have been split onto different flights or routes, and monitor quantity and weight at the flight level. This provides enhanced visibility into inventory levels, empowering shippers to improve resource planning and pickup scheduling.
- Booking Details — including flight number, status, origin/destination, arrival/departure time, quantity, weight and volume — provide clear visibility into the flight expectations compared to the tracking updates happening in real time.
“FourKites continues to be an essential partner in our ability to help our customers make informed freight forwarding decisions, keeping their timelines precise and costs under control,” said Chad Heller, Executive Vice President, Global Development at Pegasus Logistics. “We look forward to leveraging FourKites’ new air visibility solutions to strengthen supply chain logistics and enhance customer experiences around the globe.”
These new capabilities build upon FourKites’ recent significant expansion in air freight. Over the last 12 months, the company has experienced over 150% growth in air volume, and now tracks across more than 100 airlines and 17,000 airports, integrating with more than 20 major parcel providers to support high-value shipments. In addition, customers continue to benefit from FourKites’ Dynamic ETA for Air — the industry-first innovation that tracks nearly 100% of air freight with highly accurate and automated ETAs within 9 hours of arrival.
“By offering true door-to-door air visibility, FourKites is focused on providing the full picture to help customers transport high-value freight efficiently,” said Priya Rajagopalan, chief product officer at FourKites. "Shippers and freight forwarders often rely on air to transport valuable goods and to speed up shipments in case of delays. FourKites’ new capabilities, created in close collaboration with our customers, represent a meaningful step forward in integrating air transport more efficiently in global supply chains."
FourKites’ new air offerings are part of the company’s international solution suite that comprises ocean, air and rail, connecting global end-to-end supply chains through real-time visibility technology that helps shippers, carriers and 3PLs work better together. Similar to air visibility, FourKites’ Dynamic Ocean ® also includes Dynamic ETAs powered by artificial intelligence, providing customers with the market’s most accurate ETAs for ocean shipments across all lanes worldwide.
About FourKites
Leading supply chain visibility platform FourKites® extends visibility beyond transportation into yards, warehouses, stores and beyond. Tracking more than 3 million shipments daily across road, rail, ocean, air, parcel and last mile, and reaching over 200 countries and territories, FourKites combines real-time data and powerful machine learning to help companies digitise their end-to-end supply chains. More than 1,200 of the world’s most recognised brands — including 9 of the top-10 CPG and 18 of the top-20 food and beverage companies — trust FourKites to transform their business and create more agile, efficient and sustainable supply chains. To learn more, visit https://www.fourkites.com/.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230508005742/en/
Contact information
Scott Johnston
European PR Director, FourKites
+31 62 147 8442
scott.johnston@fourkites.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Sonrotoclax Data at ASH 2025 Confirm Foundational Potential Across B-cell Malignancies8.12.2025 01:00:00 EET | Press release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data on sonrotoclax, a next-generation investigational BCL2 inhibitor, demonstrating meaningful clinical benefit as monotherapy and in combination across B-cell malignancies. These data were featured at the 67th American Society of Hematology (ASH) Annual Meeting & Exposition in Orlando, Florida. The five presentations highlight durable responses in heavily pretreated patients with relapsed/refractory (R/R) mantle cell lymphoma (MCL) and additional studies showing deep, rapid, and sustained undetectable minimal residual disease (uMRD) rates with sonrotoclax-based combinations in patients with treatment-naive chronic lymphocytic leukemia (CLL), highlighting the foundational potential of this medicine. “The data we’re presenting at ASH 2025 are redefining what physicians can expect from sonrotoclax as a next-generation BCL2 inhibitor,” said Amit Agarwal, M.D., Ph.D., Chief Medical
Hemato-Oncology Trials: AOP Health Presents New Results at Top Congress ASH7.12.2025 18:00:00 EET | Press release
AOP Health continues to advance its clinical research program in myeloproliferative neoplasms, a special group of rare blood cancers. The company, specialized in rare diseases, presented the results of two scientific investigations at the 67th American Society of Hematology Association (ASH) Annual Meeting 2025 held in Orlando, FL, USA. The results provide new insights in treatment strategies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251207587915/en/ Dr. Martin Steinhart, CEO AOP Health; Photo credit: AOP Health/Studio Koekart ROP-ET and BESREMI PASS One of the clinical studies, ROP-ET, examined the use of ropeginterferon alfa-2b in people with essential thrombocythemia (ET), a disease in which the body produces too many platelets. The trial, a prospective, multicenter, single-arm phase III study, investigated the safety and efficacy of ropeginterferon alfa-2b in ET patients unable to receive available cytoreductive th
CoMotion GLOBAL 2025 Launches in Riyadh: Global Mobility Leaders Unite in Saudi Capital to Chart Urban Future7.12.2025 14:00:00 EET | Press release
Riyadh is rapidly becoming one of the world's most ambitious urban mobility laboratories, where next-generation technologies move from blueprint to real-world deployment on city streets at unprecedented scale. CoMotion GLOBAL 2025, the world's most influential gathering of urban mobility leaders, opens today in Riyadh for a three-day summit bringing together innovators from Africa, Asia, Europe, the Americas, and the Middle East. Running December 7-9, the event will explore how electrification, autonomy, AI-enabled transport, and giga-project urbanism are reshaping cities worldwide. The summit will spotlight everything from high-performance EVs and breakthrough autonomous fleets to emerging-market transport solutions and new mobility models, demonstrating how the Kingdom is opening new pathways for global mobility leadership. Strategic Partnerships Powering the Summit CoMotion GLOBAL 2025 is hosted by the Saudi Conventions & Exhibitions General Authority (SCEGA), supported by key Saudi
Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67 th American Society of Hematology (ASH) Annual Meeting6.12.2025 16:30:00 EET | Press release
Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which Ono obtained exclusive global rights for the development and commercialization of sapablursen. “In the treatment of PV, phlebotomy and cytoreductive therapy are performed as treatments for preventing thrombosis. Phlebotomy is the most common treatment for PV, in which blood
Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera6.12.2025 16:30:00 EET | Press release
Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX) and Takeda (TSE:4502/NYSE:TAK) announce that new 52-week results from the pivotal Phase 3 VERIFY study evaluating rusfertide in patients with polycythemia vera (PV) will be presented in an oral presentation at the 67th American Society of Hematology (ASH) Annual Meeting and Exposition. These findings further reinforce rusfertide’s efficacy and safety and demonstrate durability of response, with 61.9% of patients continuously treated with rusfertide maintaining absence of phlebotomy eligibility from baseline to Week 52. “The 52-week data demonstrated the sustained efficacy of rusfertide, reducing the need for patients to receive phlebotomy while maintaining hematocrit control,” said Dr. Andrew T. Kuykendall, M.D., VERIFY Lead Investigator and Associate Member in the Department of Hematology at Moffitt Cancer Center. “The 32-week VERIFY primary results were already promising, and this deeper understanding of the durability of r
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
